Latest Financial Position News

Page 21 of 464
Oliver’s Real Food Limited has reported a statutory net profit after tax of $995,000 for the half-year ended December 2025, marking a $1.82 million turnaround from the previous loss. This improvement comes despite a 6.5% revenue decline, driven by strategic store closures and disciplined cost management.
Victor Sage
Victor Sage
25 Feb 2026
Global Health Limited reports a modest half-year loss reduction alongside a steady rise in recurring SaaS revenue, signaling progress in its digital healthcare transformation.
Sophie Babbage
Sophie Babbage
25 Feb 2026
Audeara Limited reported a strong half-year revenue increase of 63.76% to $2.95 million, alongside a 57% reduction in net loss. However, the company flagged ongoing uncertainty about its ability to continue as a going concern.
Sophie Babbage
Sophie Babbage
25 Feb 2026
Star Combo Pharma reported a 23% decline in revenue to $11.9 million for the half year ended December 2025, driven by the loss of a major OEM contract and closure of its AustoYou retail business. Despite this, operating profit after tax rose 49% to $413,243, reflecting effective cost management.
Ada Torres
Ada Torres
25 Feb 2026
Vitura Health Limited reported an 8.3% rise in half-year revenues to $67.87 million, driven by medicinal cannabis sales and telehealth services, yet posted a consolidated loss of $986,341 due to margin pressures and increased costs. Leadership changes and strategic investments mark a pivotal phase for the digital health and medicinal cannabis player.
Ada Torres
Ada Torres
25 Feb 2026
Carnegie Clean Energy reported a $1.7 million loss for the half-year ending December 2025, while pushing forward with key wave energy projects and securing $2.1 million in fresh capital.
Victor Sage
Victor Sage
25 Feb 2026
Anatara Lifesciences reports a significantly reduced net loss for H1 FY2026, driven by promising pre-clinical results in its anti-obesity program and a successful $1.2 million capital raise. The company also highlights positive Phase II trial outcomes for its gastrointestinal health product GaRP.
Ada Torres
Ada Torres
25 Feb 2026
Imugene Limited reports a narrower half-year loss as it advances its promising azer-cel CAR T therapy with strong clinical results and FDA backing, supported by a $25 million capital raise.
Ada Torres
Ada Torres
25 Feb 2026
Optiscan Imaging reports a sharp 43% drop in revenue and a 43% rise in losses for H1 FY26, driven by restricted research funding in key markets. The company bolsters its balance sheet with a $17.75 million capital raise to advance clinical studies and regulatory approvals.
Ada Torres
Ada Torres
25 Feb 2026
Compumedics Limited has reported a robust half-year performance, with revenue climbing 32% to $31 million and a return to profitability, driven by strong MEG system sales and SaaS growth.
Ada Torres
Ada Torres
25 Feb 2026
Sea Forest Limited has reported a remarkable 236% increase in SeaFeed revenue for the first half of 2026, surpassing breakeven cattle commitments and securing new international partnerships.
Ada Torres
Ada Torres
25 Feb 2026
Iress Limited reported a 7.4% revenue decline to $556.3 million for FY25 but achieved a 21.5% rise in profit before tax, declaring a fully franked final dividend of 13 cents per share. The company sharpened its focus on core Wealth and Trading software businesses while advancing sustainability and AI innovation.
Sophie Babbage
Sophie Babbage
25 Feb 2026